Tizanidine Tablet
Product Images NDC 67877-613

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 67877-613). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tiz-01 (Tiz 01)

FDA Label Image

Tiz-02 (Tiz 02)

This is a chart showing the plasma concentration of Tzanidine in ng/mL with different dosing conditions (with or without food) at different hours from dosing.*

FDA Label Image

Tiz-03 (Tiz 03)

FDA Label Image

Tiz-04 (Tiz 04)

FDA Label Image

Tiz-2mg-150s (Tiz 2mg 150s)

FDA Label Image

Tiz-4mg-150s (Tiz 4mg 150s)

Each tablet contains 4 mg of tizanidine base as 4.576 mg tizanidine HCI USP. The usual dosage should be referred to the package insert for complete prescribing information. The tablets should be stored in a tight container at a temperature of 25°C (77°F), with excursions allowed between 15 to 30°C (59 to 86°F) in controlled USP room temperature. The medication should be dispensed with a child-resistant closure. This drug is manufactured by Alkem Laboratories Ltd. with Tizanidine Capsules PL 14107, and is distributed by Ascend Laboratories, LLC in Parsippany, NJ 07054. No further information is available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.